Merck (MRK) Stock Rallies Following FDA Approval of Breakthrough Cholesterol Medication

Merck (MRK) gains momentum as FDA approves Lipfendra, the first oral PCSK9 inhibitor for cholesterol, priced at $315/month with $5B+ sales potential.

The post Merck (MRK) Stock Rallies Following FDA Approval of Breakthrough Cholesterol Medication appeared first on Blockonomi.